MUMBAI, India, July 13 -- Intellectual Property India has published a patent application (202618072008 A) filed by C Therapeutics, Inc. on June 10, 2026, for Isoindolinone And Indazole Compounds For The Degradation Of Egfr.
Inventors include Nasveschuk, Christopher G.; Duplessis, Martin; Ahn, Jae Young; Hird, Alexander W.; Michael, Ryan E.; Lazarski, Kiel Number; Liang, Yanke; Jaeschke, Georg; Ricci, Antonio Filed On; Goergler, Annick; and Rueher, Daniel.
The application for the patent was published on July 10, 2026, under issue no. 28/2026.
Abstract: The invention provides compounds that degrade the epidermal growth factor receptor (EGFR) including mutant forms via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.
Disclaimer: Curated by HT Syndication.
